The aim of this study is to assess the cost-effectiveness of schema therapy compared to treatment as usual (TAU) in patients with treatment-resistant anxiety disorders. In a multicenter randomized controlled trial, patients will be assigned to receive individual schema therapy (maximum of 40 sessions) or treatment as usual (control group) within one year. The primary outcome is the difference between ST and TAU conditions in anxiety symptoms as measured with the Beck Anxiety Inventroy (BAI) at post treatment. Secondary outcomes include quality of life, societal costs, general mental health, remission from the anxiety disorders and/or comorbid affective disorders, positive and negative effects of psychotherapy, schemas and schema modes, and satisfaction. Measurements take place at baseline and after 1, 3, 6, 12, 24 and 36 months (follow-up of two years).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in the severity of anxiety symptoms
Timeframe: Screening, baseline and at 1, 3, 6, 12, 24 and 36 months after baseline.
Health-related quality of life
Timeframe: Baseline and at 1, 3, 6, 12, 24 and 36 months after baseline.
Mental health quality of life
Timeframe: Baseline and at 1, 3, 6, 12, 24 and 36 months after baseline.
Health care utilization and productivity losses
Timeframe: Baseline and at 1, 3, 6, 12, 24 and 36 months after baseline.